As RNAi Rx Efforts Progress, Some Companies Look to Use Technologies in Other Areas

Among the firms exploring areas outside of their core RNAi drug focus are Alnylam Pharmaceuticals, Marina Biotech, and RXi Pharmaceuticals.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.